COVID-19
Conditions
Keywords
oral vaccine, SARS-CoV-2, tablet vaccine
Brief summary
Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with an mRNA (messenger ribonucleic acid) vaccine for the prevention of COVID-19. Part 2: This phase will assess the efficacy of prophylactic VXA-CoV2-1.1-S against confirmed COVID-19 occurring from 7 days after second dose with a repeat-dose vaccination schedule in healthy adults compared to placebo. Safety and immunogenicity of VXA-CoV2-1.1-S will also be evaluated in this phase.
Detailed description
Part 1: This is an open-label, dose-ranging phase of the study to determine the safety and immunogenicity of an orally administered adenoviral-vector based vaccine (VXA-COV2-1.1-S) expressing a SARS-CoV-2 antigen and dsRNA adjuvant. Post screening activities, healthy adult volunteers, either naïve or prior vaccinated with an mRNA COVID-19 vaccine, aged 18 - 55 yrs old, and then 56 - 75 yrs old, will be enrolled into the study in 8 subgroups. Participants will receive either a low or a high dose of an oral tableted vaccine at Days 1 and Day 29. The total study period will last \ 2 months during the active phase, with a total 12 month safety follow-up period post last vaccination. Safety, reactogenicity and immunogenicity assessments will be performed at set times during the study active and follow-up periods. Subjects will be monitored for symptoms of COVID-19 throughout the duration of the study follow-up period. An independent data monitoring committee (IDMC) will provide safety oversight through the duration of the trial. Safety and immunogenicity data will inform on the dose selection for Part 2. Part 2: This will be a placebo-controlled phase with the vaccine dose level selected from Part 1. Subjects will receive two doses of vaccine or placebo at Days 1 and 29. Subjects will be followed as in Part 1 for safety and immunogenicity. They will also be followed for 6 months for efficacy.
Interventions
DRUGVXA-CoV2-1.1-S
COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine
OTHERPlacebo Tablets
Placebo tablets matching the active vaccine tablets
Sponsors
Vaxart
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Double-Blind, Randomized (Part 2)
Intervention model description
Open-label dose and age escalation lead in phase in naive and prior vaccinated subjects, followed by a multi-center, placebo-controlled efficacy phase.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
1. 18 - 75 years of age (inclusive) at the time of signing the Informed Consent Form (ICF). 2. Cohort 1 ONLY - Naive of any prior vaccination for the prevention of COVID-19 (tested using a rapid antibody test) at screening and within 7 days prior to the enrollment (Day 1). 3. Cohort 2 ONLY - Have received prior immunizations (both doses) with an EUA or FDA approved mRNA vaccine for the prevention of COVID-19, at least 6 months prior to enrollment (Day 1). 4. In stable and good health, without significant medical illness, based on medical history, physical examination, vital signs, and clinical laboratory tests as determined by the Investigator. 5. Safety laboratory values1 within the following range criteria at screening: 1. Laboratory values within normal range or grade 1 outside the range of normal with no clinical significance (NCS) for the following analytes:, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin, blood urea nitrogen (BUN), creatinine, glucose, potassium, and sodium 2. Laboratory values within normal range for platelet counts2 and the following coagulation tests: PT/INR, aPTT and fibrinogen 6. Body mass index (BMI) between 17 and 32 kg/m2 at screening. 7. Capable of providing signed informed consent. 8. Available for all planned visits and phone calls, and willing to complete all protocol-defined procedures and assessments (including ability and willingness to swallow multiple small enteric-coated tablets per vaccine dose). Gender and Reproductive Considerations 9. Male or female participants. Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Refer to Appendix 4 (Section 9.4). 10. Female participants must not be breastfeeding and must have a negative pregnancy test at screening and before each vaccination and fulfill one of the following criteria: 1. At least 1 year post-menopausal (defined as amenorrhea for ≥12 consecutive months prior to Screening without an alternative medical cause). Women under 60 years will need to verify post-menopausal status via a follicle-stimulating hormone (FSH) test if another option to prevent potential pregnancy will not be utilized for 30 days prior to baseline vaccination and until 60 days after the last vaccination. 2. Surgically sterile 3. Use of oral, implantable, transdermal or injectable contraceptives for 30 days prior to initial vaccination and until 60 days after the last vaccination. 4. A reliable form of contraception must be approved by the Investigator (e.g., double barrier method, Depo-Provera, intrauterine device, Norplant, oral contraceptives, contraceptive patches). 5. Not be sexually active (abstinent) or be in a relationship with partner who is sterile (must be discussed with site staff and documented).
Exclusion criteria
Medical Conditions 1. Clinically significant acute illness within 72 hours prior to vaccination defined as the presence of a moderate or severe illness (as determined by the Investigator through medical history and physical exam) (assessment may be repeated during screening period). 2. Current or known previous infection with SARS-CoV-2 or receipt of any therapeutic for the prevention or treatment of COVID-19, Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome (SARS). \[EUA or FDA approved mRNA vaccines for the prevention of SARS-CoV-2 infection taken at least 6 months prior to enrollment are permitted in Cohort 2\] 3. Individuals with the following underlying medical conditions who are at higher risk (or might be at higher risk) of severe illness from COVID-19 per the guidance from the Centers for Disease Control and Prevention (CDC): 1. Cancer, including history of cancer or treatment within past 3 years (excluding basal cell carcinoma or squamous cell carcinoma) 2. Chronic kidney disease 3. Chronic obstructive pulmonary disease (COPD) 4. Immunocompromised state from solid organ transplant, or other medical condition 5. Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies 6. Sickle cell disease 7. Uncontrolled type 2 diabetes mellitus 8. Asthma (moderate to severe) 9. Cerebrovascular disease 10. Cystic fibrosis 11. Uncontrolled hypertension or high blood pressure 12. Immunocompromised state from blood or bone marrow transplant, immune deficiencies, HIV, use of corticosteroids, or use of other immune weakening medicines 13. Neurologic conditions, such as dementia 14. Liver disease 15. Pregnancy or breast feeding 16. Pulmonary fibrosis 17. Chronic smoking (≥ 1 cigarette per day) 18. Thalassemia 19. Type 1 diabetes mellitus 4. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic. 5. Any condition that resulted in the absence or removal of the spleen. 6. Any other condition that in the clinical judgment of the Investigator would jeopardize the safety or rights of a participant participating in the study, would render the participant unable to comply with the protocol or would interfere with the evaluation of the study endpoints. Diagnostic Assessments 7. Temperature ≥38.0ºC (100.4°F) within 24 hours prior to the planned study vaccination (assessment may be repeated during screening period). 8. Positive HIV, Hepatitis B surface antigen (HBsAg) or HCV tests at the screening visit. 9. History of gastrointestinal bleeding (e.g. melena or hematochezia) Prior/Concurrent Therapy Note: The Active Period is defined as the time period from Day 1 through Week 8, or 4 weeks post last vaccination. 10. Receipt of a licensed influenza vaccine within 14 days prior to baseline vaccination or another licensed vaccine within 28 days prior to baseline vaccination, or planned administration during the study active period. 11. Use of antiviral medications , including anti-retrovirals within 1 week before vaccination or planned use during the active study period. 12. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 1 week before vaccination or planned use during the active study period. 13. Use of medications known to affect the immune function (e.g., systemic corticosteroids and others) within 14 days before vaccination or planned use during the active study period. 14. Daily use of nonsteroidal anti-inflammatory drugs, sulfonylureas, and angiotensin II blockers within 1 week before vaccination or planned use during the active study period. 15. Positive urine drug screen for drugs of abuse at screening (except for previous marijuana use); concurrent or planned use of marijuana during the active study period. 16. Administration of any investigational vaccine, drug or device within 8 weeks preceding vaccination, or planned use within the duration of the study. Other Exclusions 17. Donation or use of blood or blood products within 4 weeks prior to vaccination or planned donation during the study period. 18. Any significant hospitalization within the last year which in the opinion of the Investigator or Sponsor could interfere with study participation. 19. History of drug, alcohol or chemical abuse within 1 year of screening. 20. History of hypersensitivity or allergic reaction to any component of the investigational vaccine, including but not limited to fish gelatin. 21. Any of the following history or conditions that may lead to higher risk of clotting events and/or thrombocytopenia: 1. Family or personal history of bleeding or thrombosis 2. History of heparin-related thrombotic events, and/or receiving heparin treatments 3. History of autoimmune or inflammatory disease 4. Presence of any of the following conditions known to increase risk of thrombosis within 6 months prior to screening: * Recent surgery other than removal/biopsy of cutaneous lesions * Immobility (confined to bed or wheelchair for 3 or more successive days) * Head trauma with loss of consciousness or documented brain injury * Receipt of anticoagulants for prophylaxis of thrombosis * Recent clinically significant infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Experienced a Solicited Symptom of Reactogenicity | Up to 7 days after Dose 1 (Days 1 to 8) and Dose 2 (Days 29 to 36) | Solicited symptoms of reactogenicity were predefined systemic signs and symptoms of reactogenicity for which the participant was specifically questioned, and which were noted by the participant in their daily Solicited Symptom Diary for 7 days after each vaccination, including: * fever (any temperature 100°F or higher) * headache * myalgia (muscle pain) * abdominal pain * anorexia (defined and not eating) * nausea * vomiting * diarrhea * malaise/fatigue |
| Severity of Solicited Symptoms of Reactogenicity | Up to 7 days after Dose 1 (Days 1 to 8) and Dose 2 (Days 29 to 36) | Solicited symptoms of reactogenicity were predefined systemic signs and symptoms of reactogenicity for which the participant was specifically questioned, and which were noted by the participant in their daily Solicited Symptom Diary for 7 days after each vaccination, including: * fever (any temperature 100°F or higher) * headache * myalgia (muscle pain) * abdominal pain * anorexia (defined and not eating) * nausea * vomiting * diarrhea * malaise/fatigue Participants were instructed to rate solicited symptoms of reactogenicity that were collected in their Solicited Symptom Diary with the below grades, against pre-defined criteria as noted in the protocol: * Grade 1 - Mild * Grade 2 - Moderate * Grade 3 - Severe * Grade 4 - Life Threatening Participants with multiple solicited symptoms were only counted once, the highest severity of which was used. |
| Number of Participants Who Experienced an Unsolicited Treatment-emergent Adverse Event (TEAE) During the Active Treatment Period | Day 1 to Day 57 | A TEAE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, occurring after first dose of study drug. A serious TEAE was any TEAE that met any of the following criteria: * Resulted in death. * Was life-threatening. * Required inpatient hospitalization or prolongation of existing hospitalization. * Resulted in persistent or significant disability/incapacity. * Was a congenital anomaly/birth defect. * Was a suspected transmission of any infectious agent via a medicinal product. * Was a significant medical event, as judged by the investigator. |
| Severity of Unsolicited TEAEs During the Active Treatment Period | Day 1 to Day 57 | All unsolicited TEAEs during the active treatment period were assessed by the investigator using the below scale: * Mild: Events that required minimal or no treatment and did not interfere with the participant's daily activities. * Moderate: Events that resulted in a low level of inconvenience or concern with the therapeutic measures. Moderate events may have caused some interference with functioning. * Severe: Events that interrupted a participant's usual daily activity and may have required systemic drug therapy or other treatment. Severe events were usually incapacitating. * Life Threatening: Any adverse drug experience that placed the participant, in the view of the investigator, at immediate risk of death from the reaction as it occurred. Participants with multiple TEAEs during the active treatment period were only counted once, the highest severity of which was used. |
| Number of Participants Who Experienced a Medically Attended Adverse Event (MAAE) During the Active Treatment Period | Day 1 to Day 57 | MAAEs were defined as TEAEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits were not considered medically-attended visits. New onset of chronic illness/diseases (NOCI) and adverse events of special interest (AESIs) were collected as part of the MAAEs. As defined in the protocol, adverse events for potential immune-mediated medical conditions as well as events associated with thrombosis and thrombocytopenia were considered AESIs. |
| Severity of MAAEs During the Active Treatment Period | Day 1 to Day 57 | All MAAEs during the active treatment period were assessed by the investigator using the below scale: * Mild: Events that required minimal or no treatment and did not interfere with the participant's daily activities. * Moderate: Events that resulted in a low level of inconvenience or concern with the therapeutic measures. Moderate events may have caused some interference with functioning. * Severe: Events that interrupted a participant's usual daily activity and may have required systemic drug therapy or other treatment. Severe events were usually incapacitating. * Life Threatening: Any adverse drug experience that placed the participant, in the view of the investigator, at immediate risk of death from the reaction as it occurred. Participants with multiple MAAEs during the active treatment period were only counted once, the highest severity of which was used. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Levels of SARS-CoV2-specific Immunoglobulin G Receptor-binding Domain (IgG-RBD) Antibodies by MSD Assay | Day 1, Day 29 and Day 57 | SARS-CoV2-specific IgG-RBD antibody levels were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result. |
| Levels of SARS-CoV2-specific Immunoglobulin A Spike (IgA-S) Antibodies by MSD Assay | Day 1, Day 29 and Day 57 | SARS-CoV2-specific IgA-S antibody levels were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result. |
| Levels of SARS-CoV2-specific Immunoglobulin A Nucleocapsid (IgA-N) Antibodies by MSD Assay | Day 1, Day 29 and Day 57 | SARS-CoV2-specific IgA-N antibody levels were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result. |
| Levels of SARS-CoV2-specific Immunoglobulin A Receptor-binding Domain (IgA-RBD) Antibodies by MSD Assay | Day 1, Day 29 and Day 57 | SARS-CoV2-specific IgA-RBD antibody levels were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result. |
| Number of Participants Who Experienced a MAAE During the Safety Follow-up Period | From last dose up to 12 months post-last dose | MAAEs were defined as TEAEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits were not considered medically-attended visits. NOCI and AESIs were collected as part of the MAAEs. As defined in the protocol, adverse events for potential immune-mediated medical conditions as well as events associated with thrombosis and thrombocytopenia were considered AESIs. |
| Mean Percentage of Cluster of Differentiation 8 (CD8) T-cells Making Tumor Necrosis Factor (TNF) Alpha+ Spike (S) as Measured by Intracellular Cytokine Cytometry (ICC) | Day 1, Day 8, Day 29 and Day 36 | Mean Percentage of CD8 T-cells making TNF alpha+S were measured on specific timepoints via ICC. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result. |
| Mean Percentage of CD8 T-cells Making Interferon (IFN) Gamma+S as Measured by ICC | Day 1, Day 8, Day 29 and Day 36 | Mean Percentage of CD8 T-cells making IFN gamma+S were measured on specific timepoints via ICC. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result. |
| Levels of SARS-CoV2-specific IgA-S Antibodies in Nasal Swabs | Day 1, Day 29 and Day 57 | SARS-CoV2-specific IgA-S antibody levels in nasal swabs were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result. |
| Levels of SARS-CoV2-specific IgA-S Antibodies in Saliva Swabs | Day 1, Day 29 and Day 57 | SARS-CoV2-specific IgA-S antibody levels in saliva swabs were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result. |
| Levels of Neutralizing Serum Antibody Titers to SARS-CoV-2 | Day 1, Day 29 and Day 57 | Neutralizing Serum Antibody Titers to SARS-CoV-2 were measured on specific timepoints via qualified pseudovirus assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result. |
| Severity of MAAEs During the Safety Follow-up Period | From last dose up to 12 months post-last dose | All MAAEs during the safety follow-up period were assessed by the investigator using the below scale: * Mild: Events that required minimal or no treatment and did not interfere with the participant's daily activities. * Moderate: Events that resulted in a low level of inconvenience or concern with the therapeutic measures. Moderate events may have caused some interference with functioning. * Severe: Events that interrupted a participant's usual daily activity and may have required systemic drug therapy or other treatment. Severe events were usually incapacitating. * Life Threatening: Any adverse drug experience that placed the participant, in the view of the investigator, at immediate risk of death from the reaction as it occurred. Participants with multiple MAAEs during the safety follow-up period were only counted once, the highest severity of which was used. |
| Number of Participants Who Experienced a Serious TEAE During the Safety Follow-up Period | From last dose up to 12 months post-last dose | A TEAE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, occurring after first dose of study drug. A serious TEAE was any TEAE that met any of the following criteria: * Resulted in death. * Was life-threatening. * Required inpatient hospitalization or prolongation of existing hospitalization. * Resulted in persistent or significant disability/incapacity. * Was a congenital anomaly/birth defect. * Was a suspected transmission of any infectious agent via a medicinal product. * Was a significant medical event, as judged by the investigator. |
| Severity of Serious TEAEs During the Safety Follow-up Period | From last-dose up to 12 months post-last dose | All serious TEAEs during the active treatment period were assessed by the investigator using the below scale: * Mild: Events that required minimal or no treatment and did not interfere with the participant's daily activities. * Moderate: Events that resulted in a low level of inconvenience or concern with the therapeutic measures. Moderate events may have caused some interference with functioning. * Severe: Events that interrupted a participant's usual daily activity and may have required systemic drug therapy or other treatment. Severe events were usually incapacitating. * Life Threatening: Any adverse drug experience that placed the participant, in the view of the investigator, at immediate risk of death from the reaction as it occurred. Participants with multiple serious TEAEs during the active treatment period were only counted once, the highest severity of which was used. |
| Levels of SARS-CoV2-specific Immunoglobulin G Spike (IgG-S) Antibodies by Mesoscale Discovery (MSD) Assay | Day 1, Day 29 and Day 57 | SARS-CoV2-specific IgG-S antibody levels were measured on specific timepoints via MSD assay. For results below the lower limit of quantification (LLOQ), the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the upper limit of quantification (ULOQ), the value was replaced with the numeric portion of the original result. |
| Levels of SARS-CoV2-specific Immunoglobulin G Nucleocapsid (IgG-N) Antibodies by MSD Assay | Day 1, Day 29 and Day 57 | SARS-CoV2-specific IgG-N antibody levels were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result. |
Countries
United States
Participant flow
Recruitment details
A total of 66 participants were enrolled at 5 sites in the United States between 22 October 2021 and 09 May 2023 (follow-up period cut-off) in Part 1 of the study. Vaxart decided not to conduct Part 2 of this study, so results for Part 2 were not included in this summary.
Participants by arm
| Arm | Count |
|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log Healthy participants received VXA-CoV2-1.1-S at a dose of 1 x 10\^10 IU ± 0.5 log as an oral tablet on Day 1 and Day 29 of the 57-day active study period. Participants then entered the safety follow-up period until Month 13. | 45 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log Healthy participants received VXA-CoV2-1.1-S at a dose of 1 x 10\^11 IU ± 0.5 log as an oral tablet on Day 1 and Day 29 of the 57-day active study period. Participants then entered the safety follow-up period until Month 13. | 21 |
| Total | 66 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Death | 0 | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Lost to Follow-up | 1 | 1 | 1 | 2 | 1 | 0 |
| Overall Study | Miscellaneous | 1 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 2 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Total |
|---|---|---|---|
| Age, Customized 18 - 55 years | 25 Participants | 21 Participants | 46 Participants |
| Age, Customized 56 - 75 years | 20 Participants | 0 Participants | 20 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 10 Participants | 5 Participants | 15 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 35 Participants | 16 Participants | 51 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 6 Participants | 4 Participants | 10 Participants |
| Race/Ethnicity, Customized Black or African American | 6 Participants | 5 Participants | 11 Participants |
| Race/Ethnicity, Customized Multiple | 2 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized Other | 2 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized White | 29 Participants | 10 Participants | 39 Participants |
| Sex: Female, Male Female | 20 Participants | 10 Participants | 30 Participants |
| Sex: Female, Male Male | 25 Participants | 11 Participants | 36 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 45 | 0 / 21 | 1 / 44 | 0 / 21 |
| other Total, other adverse events | 25 / 45 | 14 / 21 | 1 / 44 | 3 / 21 |
| serious Total, serious adverse events | 1 / 45 | 0 / 21 | 3 / 44 | 0 / 21 |
Outcome results
Primary
Number of Participants Who Experienced a Medically Attended Adverse Event (MAAE) During the Active Treatment Period
MAAEs were defined as TEAEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits were not considered medically-attended visits. New onset of chronic illness/diseases (NOCI) and adverse events of special interest (AESIs) were collected as part of the MAAEs. As defined in the protocol, adverse events for potential immune-mediated medical conditions as well as events associated with thrombosis and thrombocytopenia were considered AESIs.
Time frame: Day 1 to Day 57
Population: Safety Population: Included all randomized participants who received at least one dose of the study drug. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Number of Participants Who Experienced a Medically Attended Adverse Event (MAAE) During the Active Treatment Period | 6 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Number of Participants Who Experienced a Medically Attended Adverse Event (MAAE) During the Active Treatment Period | 0 Participants |
Primary
Number of Participants Who Experienced an Unsolicited Treatment-emergent Adverse Event (TEAE) During the Active Treatment Period
A TEAE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, occurring after first dose of study drug. A serious TEAE was any TEAE that met any of the following criteria: * Resulted in death. * Was life-threatening. * Required inpatient hospitalization or prolongation of existing hospitalization. * Resulted in persistent or significant disability/incapacity. * Was a congenital anomaly/birth defect. * Was a suspected transmission of any infectious agent via a medicinal product. * Was a significant medical event, as judged by the investigator.
Time frame: Day 1 to Day 57
Population: Safety Population: Included all randomized participants who received at least one dose of the study drug. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Number of Participants Who Experienced an Unsolicited Treatment-emergent Adverse Event (TEAE) During the Active Treatment Period | Any TEAE | 10 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Number of Participants Who Experienced an Unsolicited Treatment-emergent Adverse Event (TEAE) During the Active Treatment Period | Any Serious TEAE | 1 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Number of Participants Who Experienced an Unsolicited Treatment-emergent Adverse Event (TEAE) During the Active Treatment Period | Any TEAE | 4 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Number of Participants Who Experienced an Unsolicited Treatment-emergent Adverse Event (TEAE) During the Active Treatment Period | Any Serious TEAE | 0 Participants |
Primary
Number of Participants Who Experienced a Solicited Symptom of Reactogenicity
Solicited symptoms of reactogenicity were predefined systemic signs and symptoms of reactogenicity for which the participant was specifically questioned, and which were noted by the participant in their daily Solicited Symptom Diary for 7 days after each vaccination, including: * fever (any temperature 100°F or higher) * headache * myalgia (muscle pain) * abdominal pain * anorexia (defined and not eating) * nausea * vomiting * diarrhea * malaise/fatigue
Time frame: Up to 7 days after Dose 1 (Days 1 to 8) and Dose 2 (Days 29 to 36)
Population: Safety Population: Included all randomized participants who received at least one dose of the study drug. Only participants with evaluable data at each dosing time point were included. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Number of Participants Who Experienced a Solicited Symptom of Reactogenicity | Dose 1 | 16 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Number of Participants Who Experienced a Solicited Symptom of Reactogenicity | Dose 2 | 13 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Number of Participants Who Experienced a Solicited Symptom of Reactogenicity | Dose 2 | 4 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Number of Participants Who Experienced a Solicited Symptom of Reactogenicity | Dose 1 | 10 Participants |
Primary
Severity of MAAEs During the Active Treatment Period
All MAAEs during the active treatment period were assessed by the investigator using the below scale: * Mild: Events that required minimal or no treatment and did not interfere with the participant's daily activities. * Moderate: Events that resulted in a low level of inconvenience or concern with the therapeutic measures. Moderate events may have caused some interference with functioning. * Severe: Events that interrupted a participant's usual daily activity and may have required systemic drug therapy or other treatment. Severe events were usually incapacitating. * Life Threatening: Any adverse drug experience that placed the participant, in the view of the investigator, at immediate risk of death from the reaction as it occurred. Participants with multiple MAAEs during the active treatment period were only counted once, the highest severity of which was used.
Time frame: Day 1 to Day 57
Population: Safety Population: Included all randomized participants who received at least one dose of the study drug. Only participants who experienced an MAAE during the active treatment period were included. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of MAAEs During the Active Treatment Period | Mild | 2 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of MAAEs During the Active Treatment Period | Moderate | 2 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of MAAEs During the Active Treatment Period | Severe | 2 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of MAAEs During the Active Treatment Period | Life Threatening | 0 Participants |
Primary
Severity of Solicited Symptoms of Reactogenicity
Solicited symptoms of reactogenicity were predefined systemic signs and symptoms of reactogenicity for which the participant was specifically questioned, and which were noted by the participant in their daily Solicited Symptom Diary for 7 days after each vaccination, including: * fever (any temperature 100°F or higher) * headache * myalgia (muscle pain) * abdominal pain * anorexia (defined and not eating) * nausea * vomiting * diarrhea * malaise/fatigue Participants were instructed to rate solicited symptoms of reactogenicity that were collected in their Solicited Symptom Diary with the below grades, against pre-defined criteria as noted in the protocol: * Grade 1 - Mild * Grade 2 - Moderate * Grade 3 - Severe * Grade 4 - Life Threatening Participants with multiple solicited symptoms were only counted once, the highest severity of which was used.
Time frame: Up to 7 days after Dose 1 (Days 1 to 8) and Dose 2 (Days 29 to 36)
Population: Safety Population: Included all randomized participants who received at least one dose of the study drug and experienced a solicited symptom of reactogenicity. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received. The overall number of participants analyzed is inclusive of participants all participants with symptoms following Dose 1 and/or Dose 2.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 1 | Grade 1 - Mild | 11 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 1 | Grade 2 - Moderate | 5 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 1 | Grade 3 - Severe | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 1 | Grade 4 - Life Threatening | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 2 | Grade 1 - Mild | 7 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 2 | Grade 2 - Moderate | 6 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 2 | Grade 3 - Severe | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 2 | Grade 4 - Life Threatening | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 1 | Grade 4 - Life Threatening | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 1 | Grade 1 - Mild | 8 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 2 | Grade 2 - Moderate | 1 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 2 | Grade 4 - Life Threatening | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 1 | Grade 2 - Moderate | 2 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 2 | Grade 1 - Mild | 3 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 1 | Grade 3 - Severe | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Solicited Symptoms of Reactogenicity | Dose 2 | Grade 3 - Severe | 0 Participants |
Primary
Severity of Unsolicited TEAEs During the Active Treatment Period
All unsolicited TEAEs during the active treatment period were assessed by the investigator using the below scale: * Mild: Events that required minimal or no treatment and did not interfere with the participant's daily activities. * Moderate: Events that resulted in a low level of inconvenience or concern with the therapeutic measures. Moderate events may have caused some interference with functioning. * Severe: Events that interrupted a participant's usual daily activity and may have required systemic drug therapy or other treatment. Severe events were usually incapacitating. * Life Threatening: Any adverse drug experience that placed the participant, in the view of the investigator, at immediate risk of death from the reaction as it occurred. Participants with multiple TEAEs during the active treatment period were only counted once, the highest severity of which was used.
Time frame: Day 1 to Day 57
Population: Safety Population: Included all randomized participants who received at least 1 dose of study drug \& experienced an unsolicited TEAE during the active treatment period. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures \& Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received. The overall number of participants analyzed is inclusive of participants all participants with symptoms following Dose 1 \&/or Dose 2.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any TEAE | Mild | 4 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any TEAE | Moderate | 4 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any TEAE | Severe | 2 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any TEAE | Life Threatening | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any Serious TEAE | Mild | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any Serious TEAE | Moderate | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any Serious TEAE | Severe | 1 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any Serious TEAE | Life Threatening | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any Serious TEAE | Life Threatening | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any TEAE | Mild | 3 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any Serious TEAE | Mild | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any TEAE | Moderate | 1 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any Serious TEAE | Severe | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any TEAE | Severe | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any Serious TEAE | Moderate | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of Unsolicited TEAEs During the Active Treatment Period | Any TEAE | Life Threatening | 0 Participants |
Secondary
Levels of Neutralizing Serum Antibody Titers to SARS-CoV-2
Neutralizing Serum Antibody Titers to SARS-CoV-2 were measured on specific timepoints via qualified pseudovirus assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result.
Time frame: Day 1, Day 29 and Day 57
Population: Per Protocol Population: Included all participants who were enrolled and received at least 1 dose of study drug who were free from major protocol violations. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of Neutralizing Serum Antibody Titers to SARS-CoV-2 | Day 1 | 101.2 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of Neutralizing Serum Antibody Titers to SARS-CoV-2 | Day 29 | 123.6 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of Neutralizing Serum Antibody Titers to SARS-CoV-2 | Day 57 | 150.2 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of Neutralizing Serum Antibody Titers to SARS-CoV-2 | Day 1 | 81.7 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of Neutralizing Serum Antibody Titers to SARS-CoV-2 | Day 29 | 129.5 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of Neutralizing Serum Antibody Titers to SARS-CoV-2 | Day 57 | 147.2 AU/mL |
p-value: 0.946Wilcoxon rank sum tests
Secondary
Levels of SARS-CoV2-specific IgA-S Antibodies in Nasal Swabs
SARS-CoV2-specific IgA-S antibody levels in nasal swabs were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result.
Time frame: Day 1, Day 29 and Day 57
Population: Per Protocol Population: Included all participants who were enrolled and received at least 1 dose of study drug who were free from major protocol violations. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Nasal Swabs | Day 1 | 0.142 AU IgA/ng Total IgA | Standard Deviation 0.3723 |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Nasal Swabs | Day 29 | 0.874 AU IgA/ng Total IgA | Standard Deviation 2.9889 |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Nasal Swabs | Day 57 | 0.203 AU IgA/ng Total IgA | Standard Deviation 0.5061 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Nasal Swabs | Day 1 | 0.102 AU IgA/ng Total IgA | Standard Deviation 0.1648 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Nasal Swabs | Day 29 | 0.091 AU IgA/ng Total IgA | Standard Deviation 0.1178 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Nasal Swabs | Day 57 | 0.374 AU IgA/ng Total IgA | Standard Deviation 1.4455 |
p-value: 0.356Wilcoxon rank sum tests
Secondary
Levels of SARS-CoV2-specific IgA-S Antibodies in Saliva Swabs
SARS-CoV2-specific IgA-S antibody levels in saliva swabs were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result.
Time frame: Day 1, Day 29 and Day 57
Population: Per Protocol Population: Included all participants who were enrolled and received at least 1 dose of study drug who were free from major protocol violations. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Saliva Swabs | Day 1 | 0.028 AU IgA/ng Total IgA | Standard Deviation 0.0341 |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Saliva Swabs | Day 29 | 0.070 AU IgA/ng Total IgA | Standard Deviation 0.2479 |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Saliva Swabs | Day 57 | 0.058 AU IgA/ng Total IgA | Standard Deviation 0.1275 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Saliva Swabs | Day 1 | 0.062 AU IgA/ng Total IgA | Standard Deviation 0.1541 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Saliva Swabs | Day 29 | 0.048 AU IgA/ng Total IgA | Standard Deviation 0.0883 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific IgA-S Antibodies in Saliva Swabs | Day 57 | 0.047 AU IgA/ng Total IgA | Standard Deviation 0.0652 |
p-value: 0.267Wilcoxon rank sum tests
Secondary
Levels of SARS-CoV2-specific Immunoglobulin A Nucleocapsid (IgA-N) Antibodies by MSD Assay
SARS-CoV2-specific IgA-N antibody levels were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result.
Time frame: Day 1, Day 29 and Day 57
Population: Per Protocol Population: Included all participants who were enrolled and received at least 1 dose of study drug who were free from major protocol violations. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Nucleocapsid (IgA-N) Antibodies by MSD Assay | Day 1 | 355.2 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Nucleocapsid (IgA-N) Antibodies by MSD Assay | Day 29 | 367.8 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Nucleocapsid (IgA-N) Antibodies by MSD Assay | Day 57 | 449.0 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Nucleocapsid (IgA-N) Antibodies by MSD Assay | Day 1 | 312.9 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Nucleocapsid (IgA-N) Antibodies by MSD Assay | Day 29 | 264.9 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Nucleocapsid (IgA-N) Antibodies by MSD Assay | Day 57 | 260.5 AU/mL |
p-value: 0.257Wilcoxon rank sum tests
Secondary
Levels of SARS-CoV2-specific Immunoglobulin A Receptor-binding Domain (IgA-RBD) Antibodies by MSD Assay
SARS-CoV2-specific IgA-RBD antibody levels were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result.
Time frame: Day 1, Day 29 and Day 57
Population: Per Protocol Population: Included all participants who were enrolled and received at least 1 dose of study drug who were free from major protocol violations. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Receptor-binding Domain (IgA-RBD) Antibodies by MSD Assay | Day 1 | 745.1 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Receptor-binding Domain (IgA-RBD) Antibodies by MSD Assay | Day 29 | 893.5 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Receptor-binding Domain (IgA-RBD) Antibodies by MSD Assay | Day 57 | 1122.2 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Receptor-binding Domain (IgA-RBD) Antibodies by MSD Assay | Day 1 | 562.7 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Receptor-binding Domain (IgA-RBD) Antibodies by MSD Assay | Day 29 | 913.9 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Receptor-binding Domain (IgA-RBD) Antibodies by MSD Assay | Day 57 | 875.9 AU/mL |
p-value: 0.748Wilcoxon rank sum tests
Secondary
Levels of SARS-CoV2-specific Immunoglobulin A Spike (IgA-S) Antibodies by MSD Assay
SARS-CoV2-specific IgA-S antibody levels were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result.
Time frame: Day 1, Day 29 and Day 57
Population: Per Protocol Population: Included all participants who were enrolled and received at least 1 dose of study drug who were free from major protocol violations. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Spike (IgA-S) Antibodies by MSD Assay | Day 1 | 928.4 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Spike (IgA-S) Antibodies by MSD Assay | Day 29 | 1184.5 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Spike (IgA-S) Antibodies by MSD Assay | Day 57 | 1595.4 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Spike (IgA-S) Antibodies by MSD Assay | Day 1 | 809.8 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Spike (IgA-S) Antibodies by MSD Assay | Day 29 | 1252.3 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin A Spike (IgA-S) Antibodies by MSD Assay | Day 57 | 1302.9 AU/mL |
p-value: 0.678Wilcoxon rank sum tests
Secondary
Levels of SARS-CoV2-specific Immunoglobulin G Nucleocapsid (IgG-N) Antibodies by MSD Assay
SARS-CoV2-specific IgG-N antibody levels were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result.
Time frame: Day 1, Day 29 and Day 57
Population: Per Protocol Population: Included all participants with evaluable data at each time point who were enrolled and received at least 1 dose of study drug who were free from major protocol violations. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Nucleocapsid (IgG-N) Antibodies by MSD Assay | Day 1 | 360.3 arbitrary units per milliliter (AU/mL) |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Nucleocapsid (IgG-N) Antibodies by MSD Assay | Day 29 | 593.3 arbitrary units per milliliter (AU/mL) |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Nucleocapsid (IgG-N) Antibodies by MSD Assay | Day 57 | 898.2 arbitrary units per milliliter (AU/mL) |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Nucleocapsid (IgG-N) Antibodies by MSD Assay | Day 1 | 1516 arbitrary units per milliliter (AU/mL) |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Nucleocapsid (IgG-N) Antibodies by MSD Assay | Day 29 | 1301.6 arbitrary units per milliliter (AU/mL) |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Nucleocapsid (IgG-N) Antibodies by MSD Assay | Day 57 | 1192.4 arbitrary units per milliliter (AU/mL) |
p-value: 0.5Wilcoxon rank sum tests
Secondary
Levels of SARS-CoV2-specific Immunoglobulin G Receptor-binding Domain (IgG-RBD) Antibodies by MSD Assay
SARS-CoV2-specific IgG-RBD antibody levels were measured on specific timepoints via MSD assay. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result.
Time frame: Day 1, Day 29 and Day 57
Population: Per Protocol Population: Included all participants who were enrolled and received at least 1 dose of study drug who were free from major protocol violations. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Receptor-binding Domain (IgG-RBD) Antibodies by MSD Assay | Day 1 | 2597.0 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Receptor-binding Domain (IgG-RBD) Antibodies by MSD Assay | Day 29 | 3513.2 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Receptor-binding Domain (IgG-RBD) Antibodies by MSD Assay | Day 57 | 6553.4 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Receptor-binding Domain (IgG-RBD) Antibodies by MSD Assay | Day 1 | 2570.5 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Receptor-binding Domain (IgG-RBD) Antibodies by MSD Assay | Day 29 | 4520.7 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Receptor-binding Domain (IgG-RBD) Antibodies by MSD Assay | Day 57 | 5825.8 AU/mL |
p-value: 0.912Wilcoxon rank sum tests
Secondary
Levels of SARS-CoV2-specific Immunoglobulin G Spike (IgG-S) Antibodies by Mesoscale Discovery (MSD) Assay
SARS-CoV2-specific IgG-S antibody levels were measured on specific timepoints via MSD assay. For results below the lower limit of quantification (LLOQ), the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the upper limit of quantification (ULOQ), the value was replaced with the numeric portion of the original result.
Time frame: Day 1, Day 29 and Day 57
Population: Per Protocol Population: Included all participants who were enrolled and received at least 1 dose of study drug who were free from major protocol violations. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Spike (IgG-S) Antibodies by Mesoscale Discovery (MSD) Assay | Day 1 | 4708.7 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Spike (IgG-S) Antibodies by Mesoscale Discovery (MSD) Assay | Day 29 | 6693.2 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Spike (IgG-S) Antibodies by Mesoscale Discovery (MSD) Assay | Day 57 | 12348.6 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Spike (IgG-S) Antibodies by Mesoscale Discovery (MSD) Assay | Day 1 | 6323.8 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Spike (IgG-S) Antibodies by Mesoscale Discovery (MSD) Assay | Day 29 | 10097.1 AU/mL |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Levels of SARS-CoV2-specific Immunoglobulin G Spike (IgG-S) Antibodies by Mesoscale Discovery (MSD) Assay | Day 57 | 12868.1 AU/mL |
p-value: 0.953Wilcoxon rank sum tests
Secondary
Mean Percentage of CD8 T-cells Making Interferon (IFN) Gamma+S as Measured by ICC
Mean Percentage of CD8 T-cells making IFN gamma+S were measured on specific timepoints via ICC. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result.
Time frame: Day 1, Day 8, Day 29 and Day 36
Population: Per Protocol Population: Included all participants who were enrolled and received at least 1 dose of study drug who were free from major protocol violations. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Mean Percentage of CD8 T-cells Making Interferon (IFN) Gamma+S as Measured by ICC | Day 1 | 0.349 percentage of CD8 T-cells | Standard Deviation 0.2933 |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Mean Percentage of CD8 T-cells Making Interferon (IFN) Gamma+S as Measured by ICC | Day 29 | 0.517 percentage of CD8 T-cells | Standard Deviation 0.5043 |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Mean Percentage of CD8 T-cells Making Interferon (IFN) Gamma+S as Measured by ICC | Day 8 | 0.287 percentage of CD8 T-cells | Standard Deviation 0.3369 |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Mean Percentage of CD8 T-cells Making Interferon (IFN) Gamma+S as Measured by ICC | Day 36 | 0.712 percentage of CD8 T-cells | Standard Deviation 0.6597 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Mean Percentage of CD8 T-cells Making Interferon (IFN) Gamma+S as Measured by ICC | Day 8 | 0.308 percentage of CD8 T-cells | Standard Deviation 0.434 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Mean Percentage of CD8 T-cells Making Interferon (IFN) Gamma+S as Measured by ICC | Day 1 | 0.440 percentage of CD8 T-cells | Standard Deviation 0.4038 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Mean Percentage of CD8 T-cells Making Interferon (IFN) Gamma+S as Measured by ICC | Day 36 | 0.608 percentage of CD8 T-cells | Standard Deviation 0.5592 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Mean Percentage of CD8 T-cells Making Interferon (IFN) Gamma+S as Measured by ICC | Day 29 | 0.536 percentage of CD8 T-cells | Standard Deviation 0.5142 |
Secondary
Mean Percentage of Cluster of Differentiation 8 (CD8) T-cells Making Tumor Necrosis Factor (TNF) Alpha+ Spike (S) as Measured by Intracellular Cytokine Cytometry (ICC)
Mean Percentage of CD8 T-cells making TNF alpha+S were measured on specific timepoints via ICC. For results below the LLOQ, the value was replaced with 1/2 the numeric portion of the original result rounded up to nearest integer. For results above the ULOQ, the value was replaced with the numeric portion of the original result.
Time frame: Day 1, Day 8, Day 29 and Day 36
Population: Per Protocol Population: Included all participants who were enrolled and received at least 1 dose of study drug who were free from major protocol violations. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Mean Percentage of Cluster of Differentiation 8 (CD8) T-cells Making Tumor Necrosis Factor (TNF) Alpha+ Spike (S) as Measured by Intracellular Cytokine Cytometry (ICC) | Day 1 | 0.071 percentage of CD8 T-cells | Standard Deviation 0.1352 |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Mean Percentage of Cluster of Differentiation 8 (CD8) T-cells Making Tumor Necrosis Factor (TNF) Alpha+ Spike (S) as Measured by Intracellular Cytokine Cytometry (ICC) | Day 8 | 0.046 percentage of CD8 T-cells | Standard Deviation 0.075 |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Mean Percentage of Cluster of Differentiation 8 (CD8) T-cells Making Tumor Necrosis Factor (TNF) Alpha+ Spike (S) as Measured by Intracellular Cytokine Cytometry (ICC) | Day 29 | 0.080 percentage of CD8 T-cells | Standard Deviation 0.1671 |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Mean Percentage of Cluster of Differentiation 8 (CD8) T-cells Making Tumor Necrosis Factor (TNF) Alpha+ Spike (S) as Measured by Intracellular Cytokine Cytometry (ICC) | Day 36 | 0.067 percentage of CD8 T-cells | Standard Deviation 0.0702 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Mean Percentage of Cluster of Differentiation 8 (CD8) T-cells Making Tumor Necrosis Factor (TNF) Alpha+ Spike (S) as Measured by Intracellular Cytokine Cytometry (ICC) | Day 36 | 0.122 percentage of CD8 T-cells | Standard Deviation 0.2132 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Mean Percentage of Cluster of Differentiation 8 (CD8) T-cells Making Tumor Necrosis Factor (TNF) Alpha+ Spike (S) as Measured by Intracellular Cytokine Cytometry (ICC) | Day 1 | 0.081 percentage of CD8 T-cells | Standard Deviation 0.0999 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Mean Percentage of Cluster of Differentiation 8 (CD8) T-cells Making Tumor Necrosis Factor (TNF) Alpha+ Spike (S) as Measured by Intracellular Cytokine Cytometry (ICC) | Day 29 | 0.089 percentage of CD8 T-cells | Standard Deviation 0.1538 |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Mean Percentage of Cluster of Differentiation 8 (CD8) T-cells Making Tumor Necrosis Factor (TNF) Alpha+ Spike (S) as Measured by Intracellular Cytokine Cytometry (ICC) | Day 8 | 0.009 percentage of CD8 T-cells | Standard Deviation 0.0234 |
Secondary
Number of Participants Who Experienced a MAAE During the Safety Follow-up Period
MAAEs were defined as TEAEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits were not considered medically-attended visits. NOCI and AESIs were collected as part of the MAAEs. As defined in the protocol, adverse events for potential immune-mediated medical conditions as well as events associated with thrombosis and thrombocytopenia were considered AESIs.
Time frame: From last dose up to 12 months post-last dose
Population: Safety Population: Included all randomized participants who received at least one dose of the study drug. Only participants who entered the safety follow-up period were included. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Number of Participants Who Experienced a MAAE During the Safety Follow-up Period | 5 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Number of Participants Who Experienced a MAAE During the Safety Follow-up Period | 2 Participants |
Secondary
Number of Participants Who Experienced a Serious TEAE During the Safety Follow-up Period
A TEAE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, occurring after first dose of study drug. A serious TEAE was any TEAE that met any of the following criteria: * Resulted in death. * Was life-threatening. * Required inpatient hospitalization or prolongation of existing hospitalization. * Resulted in persistent or significant disability/incapacity. * Was a congenital anomaly/birth defect. * Was a suspected transmission of any infectious agent via a medicinal product. * Was a significant medical event, as judged by the investigator.
Time frame: From last dose up to 12 months post-last dose
Population: Safety Population: Included all randomized participants who received at least one dose of the study drug. Only participants who entered the safety follow-up period were included. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Number of Participants Who Experienced a Serious TEAE During the Safety Follow-up Period | 3 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Number of Participants Who Experienced a Serious TEAE During the Safety Follow-up Period | 0 Participants |
Secondary
Severity of MAAEs During the Safety Follow-up Period
All MAAEs during the safety follow-up period were assessed by the investigator using the below scale: * Mild: Events that required minimal or no treatment and did not interfere with the participant's daily activities. * Moderate: Events that resulted in a low level of inconvenience or concern with the therapeutic measures. Moderate events may have caused some interference with functioning. * Severe: Events that interrupted a participant's usual daily activity and may have required systemic drug therapy or other treatment. Severe events were usually incapacitating. * Life Threatening: Any adverse drug experience that placed the participant, in the view of the investigator, at immediate risk of death from the reaction as it occurred. Participants with multiple MAAEs during the safety follow-up period were only counted once, the highest severity of which was used.
Time frame: From last dose up to 12 months post-last dose
Population: Safety Population: Included all randomized participants who received at least one dose of the study drug. Only participants who experienced an MAAE during the safety follow-up period were included. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of MAAEs During the Safety Follow-up Period | Mild | 1 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of MAAEs During the Safety Follow-up Period | Moderate | 2 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of MAAEs During the Safety Follow-up Period | Severe | 2 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of MAAEs During the Safety Follow-up Period | Life Threatening | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of MAAEs During the Safety Follow-up Period | Life Threatening | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of MAAEs During the Safety Follow-up Period | Mild | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of MAAEs During the Safety Follow-up Period | Severe | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^11 IU ± 0.5 Log | Severity of MAAEs During the Safety Follow-up Period | Moderate | 2 Participants |
Secondary
Severity of Serious TEAEs During the Safety Follow-up Period
All serious TEAEs during the active treatment period were assessed by the investigator using the below scale: * Mild: Events that required minimal or no treatment and did not interfere with the participant's daily activities. * Moderate: Events that resulted in a low level of inconvenience or concern with the therapeutic measures. Moderate events may have caused some interference with functioning. * Severe: Events that interrupted a participant's usual daily activity and may have required systemic drug therapy or other treatment. Severe events were usually incapacitating. * Life Threatening: Any adverse drug experience that placed the participant, in the view of the investigator, at immediate risk of death from the reaction as it occurred. Participants with multiple serious TEAEs during the active treatment period were only counted once, the highest severity of which was used.
Time frame: From last-dose up to 12 months post-last dose
Population: Safety Population: Included all randomized participants who received at least one dose of the study drug. Only participants who experienced a serious TEAE during the safety follow-up period were included. As pre-specified in Protocol Section 8.3, Baseline Characteristics, Outcome Measures and Adverse Event analysis were summarized by vaccine group according to the study drugs they actually received.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Serious TEAEs During the Safety Follow-up Period | Life Threatening | 1 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Serious TEAEs During the Safety Follow-up Period | Mild | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Serious TEAEs During the Safety Follow-up Period | Moderate | 0 Participants |
| VXA-CoV2-1.1-S: 1 x 10^10 IU ± 0.5 Log | Severity of Serious TEAEs During the Safety Follow-up Period | Severe | 2 Participants |